As of 2026-03-15, the Relative Valuation of Cytosorbents Corp (CTSO) is (5.93) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.71 USD, the upside of Cytosorbents Corp based on Relative Valuation is -937.9%.
The range of the Relative Valuation is (6.09) - (5.88) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 36.1x - 41.5x | 38.2x |
| Forward P/E multiples | 30.6x - 34.9x | 32.2x |
| Fair Price | (6.09) - (5.88) | (5.93) |
| Upside | -960.4% - -930.9% | -937.9% |
| Date | P/E |
| 2026-03-13 | -4.20 |
| 2026-03-12 | -4.31 |
| 2026-03-11 | -4.30 |
| 2026-03-10 | -4.64 |
| 2026-03-09 | -4.80 |
| 2026-03-06 | -4.73 |
| 2026-03-05 | -4.78 |
| 2026-03-04 | -4.69 |
| 2026-03-03 | -4.75 |
| 2026-03-02 | -4.44 |
| 2026-02-27 | -4.46 |
| 2026-02-26 | -4.31 |
| 2026-02-25 | -4.22 |
| 2026-02-24 | -4.09 |
| 2026-02-23 | -4.03 |
| 2026-02-20 | -3.80 |
| 2026-02-19 | -3.85 |
| 2026-02-18 | -3.85 |
| 2026-02-17 | -3.80 |
| 2026-02-13 | -3.81 |
| 2026-02-12 | -3.77 |
| 2026-02-11 | -3.68 |
| 2026-02-10 | -3.97 |
| 2026-02-09 | -3.98 |
| 2026-02-06 | -3.99 |
| 2026-02-05 | -3.74 |
| 2026-02-04 | -3.98 |
| 2026-02-03 | -4.06 |
| 2026-02-02 | -4.01 |
| 2026-01-30 | -3.74 |
| 2026-01-29 | -3.91 |
| 2026-01-28 | -4.05 |
| 2026-01-27 | -4.02 |
| 2026-01-26 | -3.92 |
| 2026-01-23 | -4.03 |
| 2026-01-22 | -4.01 |
| 2026-01-21 | -4.04 |
| 2026-01-20 | -4.02 |
| 2026-01-16 | -4.16 |
| 2026-01-15 | -4.10 |
| 2026-01-14 | -4.26 |
| 2026-01-13 | -4.33 |
| 2026-01-12 | -4.16 |
| 2026-01-09 | -3.98 |
| 2026-01-08 | -3.99 |
| 2026-01-07 | -4.03 |
| 2026-01-06 | -4.04 |
| 2026-01-05 | -3.95 |
| 2026-01-02 | -3.89 |
| 2025-12-31 | -3.79 |